BRPI0510617A - uso de expressão de il-17 para prever inflamação de pele; processos de tratamento - Google Patents

uso de expressão de il-17 para prever inflamação de pele; processos de tratamento

Info

Publication number
BRPI0510617A
BRPI0510617A BRPI0510617-6A BRPI0510617A BRPI0510617A BR PI0510617 A BRPI0510617 A BR PI0510617A BR PI0510617 A BRPI0510617 A BR PI0510617A BR PI0510617 A BRPI0510617 A BR PI0510617A
Authority
BR
Brazil
Prior art keywords
expression
skin inflammation
treatment processes
predict skin
predict
Prior art date
Application number
BRPI0510617-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Robert A Kastelein
Terrill K Mcclanahan
Erin Murphy
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of BRPI0510617A publication Critical patent/BRPI0510617A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BRPI0510617-6A 2004-05-03 2005-05-02 uso de expressão de il-17 para prever inflamação de pele; processos de tratamento BRPI0510617A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56774704P 2004-05-03 2004-05-03
PCT/US2005/014720 WO2005108616A1 (en) 2004-05-03 2005-05-02 Use of il-17 expression to predict skin inflammation; methods of treatment

Publications (1)

Publication Number Publication Date
BRPI0510617A true BRPI0510617A (pt) 2007-10-30

Family

ID=34967584

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510617-6A BRPI0510617A (pt) 2004-05-03 2005-05-02 uso de expressão de il-17 para prever inflamação de pele; processos de tratamento

Country Status (11)

Country Link
US (2) US7501247B2 (enExample)
EP (1) EP1761643A1 (enExample)
JP (1) JP2007535930A (enExample)
CN (1) CN1993480A (enExample)
AU (1) AU2005241020B2 (enExample)
BR (1) BRPI0510617A (enExample)
CA (1) CA2565566A1 (enExample)
MX (1) MXPA06012754A (enExample)
NO (1) NO20065560L (enExample)
WO (1) WO2005108616A1 (enExample)
ZA (1) ZA200609140B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7422743B2 (en) * 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
US20070160576A1 (en) * 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
DK1576011T3 (da) 2002-10-30 2009-11-30 Genentech Inc Inhibering af IL-17 produktion
US7247711B2 (en) * 2003-05-09 2007-07-24 Centocor, Inc. IL-23p40 specific antibody
BRPI0510617A (pt) * 2004-05-03 2007-10-30 Schering Corp uso de expressão de il-17 para prever inflamação de pele; processos de tratamento
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
EP1671642A1 (en) * 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
US7704503B2 (en) * 2005-02-14 2010-04-27 Wyeth Llc Use of IL-17F in diagnosis and therapy of airway inflammation
PT1896073E (pt) 2005-06-30 2013-05-28 Janssen Biotech Inc Composições, métodos e aplicações de anticorpos anti-il-23
CN101296706B (zh) * 2005-09-01 2011-11-30 先灵公司 Il-23和il-17拮抗剂治疗自身免疫性眼部炎性疾病的用途
AU2006330411B2 (en) 2005-12-29 2012-07-12 Janssen Biotech, Inc. Human anti-IL-23 antibodies, compositions, methods and uses
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
AU2007261019A1 (en) * 2006-06-19 2007-12-27 Wyeth Methods of modulating IL-22 and IL-17
US7846443B2 (en) 2006-08-11 2010-12-07 Schering Corporation Antibodies to IL-17A
EP2417974A1 (en) * 2007-02-28 2012-02-15 Schering Corporation Combination therapy for treatment of immune disorders
WO2008134659A2 (en) * 2007-04-27 2008-11-06 Zymogenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
KR20170023209A (ko) 2008-05-05 2017-03-02 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
EP2294216A4 (en) 2008-05-14 2011-11-23 Dermtech Int DIAGNOSIS OF MELANOMA AND SOLAR LENTIGO BY ANALYSIS OF NUCLEIC ACIDS
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
CN108451968A (zh) * 2009-04-15 2018-08-28 西北大学 寡核苷酸功能化的纳米颗粒的递送
PE20120815A1 (es) 2009-05-05 2012-07-08 Novimmune Sa Anticuerpos anti il-17f y metodos de uso de los mismos
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
AU2010313304B2 (en) 2009-10-30 2015-08-20 Janssen Biotech, Inc. IL-17A antagonists
WO2012061448A1 (en) 2010-11-04 2012-05-10 Boehringer Ingelheim International Gmbh Anti-il-23 antibodies
JP6279467B2 (ja) * 2011-06-27 2018-02-14 ガルデルマ・リサーチ・アンド・デヴェロップメント ざ瘡についての新規ｔｈ１７分化マーカーおよびその使用
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
US11078265B2 (en) 2012-05-03 2021-08-03 Boehringer Ingelheim International Gmbh Anti-IL-23 antibodies
CN104884473B (zh) 2012-05-22 2019-12-03 百时美施贵宝公司 Il-17a/f il-23双特异性抗体及其应用
WO2016014775A1 (en) 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
WO2016036918A1 (en) 2014-09-03 2016-03-10 Boehringer Ingelheim International Gmbh Compound targeting il-23a and tnf-alpha and uses thereof
BR112017014684A2 (en) 2015-02-04 2018-01-09 Boehringer Ingelheim International Gmbh methods of treatment of inflammatory diseases
JP2018521047A (ja) * 2015-07-16 2018-08-02 イーライ リリー アンド カンパニー 掻痒の治療
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
KR102617833B1 (ko) 2016-05-06 2023-12-27 엑시큐어 오퍼레이팅 컴퍼니 인터류킨 17 수용체 mRNA의 특이적 녹다운을 위한 안티센스 올리고뉴클레오티드 (ASO)를 제시하는 리포좀성 구형 핵산 (SNA) 구축물
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
US11976332B2 (en) 2018-02-14 2024-05-07 Dermtech, Inc. Gene classifiers and uses thereof in non-melanoma skin cancers
CA3092551A1 (en) 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
AU2019266226A1 (en) 2018-05-09 2020-12-03 Dermtech, Inc. Novel gene classifiers and uses thereof in autoimmune diseases
BR112021009287A2 (pt) 2018-11-20 2021-10-26 Janssen Biotech, Inc. Método seguro e eficaz para tratar psoríase com anticorpo específico anti-il-23
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
EP4596046A3 (en) 2020-05-21 2025-10-22 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046420A2 (en) * 1999-12-23 2001-06-28 Genentech, Inc. Il-17 and il-17r homologous polypeptides and therapeutic uses thereof
US6482923B1 (en) * 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
NZ508878A (en) * 1998-05-15 2003-08-29 Genentech Inc IL-17B and IL-17Cactive variants of IL-17 which stimulates epithelial, endothelial and fibroblastic cells
US20030083231A1 (en) 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
JP2003527104A (ja) * 1999-12-23 2003-09-16 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療上の用途
EP1287130B2 (en) * 2000-05-10 2017-07-26 Merck Sharp & Dohme Corp. Mammalian cytokine receptor subunit proteins, related reagents and methods
AU2002326285A1 (en) * 2001-01-25 2003-01-02 Zymogenetics, Inc. Method for treating psoriasis by using an il-17d antagonist
CA2442134A1 (en) * 2001-03-29 2002-10-10 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
DK1576011T3 (da) * 2002-10-30 2009-11-30 Genentech Inc Inhibering af IL-17 produktion
WO2004058178A2 (en) * 2002-12-23 2004-07-15 Schering Corporation Uses of mammalian cytokine; related reagents
DE60336930D1 (de) 2002-12-31 2011-06-09 Schering Corp IL-27 et IL-2 pour le traitement du cancer
US7247711B2 (en) * 2003-05-09 2007-07-24 Centocor, Inc. IL-23p40 specific antibody
EP1641822B1 (en) 2003-07-08 2013-05-15 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
US7501427B2 (en) * 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US7183057B2 (en) 2004-03-31 2007-02-27 Dermtech International Tape stripping methods for analysis of skin disease and pathological skin state
US20050287593A1 (en) * 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
BRPI0510617A (pt) * 2004-05-03 2007-10-30 Schering Corp uso de expressão de il-17 para prever inflamação de pele; processos de tratamento

Also Published As

Publication number Publication date
CN1993480A (zh) 2007-07-04
US20050244874A1 (en) 2005-11-03
EP1761643A1 (en) 2007-03-14
US7776540B2 (en) 2010-08-17
ZA200609140B (en) 2007-11-28
US20090028860A1 (en) 2009-01-29
AU2005241020A1 (en) 2005-11-17
MXPA06012754A (es) 2007-02-19
JP2007535930A (ja) 2007-12-13
US7501247B2 (en) 2009-03-10
CA2565566A1 (en) 2005-11-17
NO20065560L (no) 2006-12-01
AU2005241020B2 (en) 2008-07-10
WO2005108616A1 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
BRPI0510617A (pt) uso de expressão de il-17 para prever inflamação de pele; processos de tratamento
NL301145I2 (nl) Tirbanibulin
CY1120961T1 (el) Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος
BR112016008694A2 (pt) Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
CY1118760T1 (el) Τροποποιημενα αντισωματα εναντι il-23
BR112016018205A8 (pt) métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
BRPI0907135B8 (pt) uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
BRPI0916138A2 (pt) "método de tratamento de um sujeito diagnosticado com câncer de mama localmente, kit para tratar câncer de mama metastático em um sujeito humano, uso de um anticorpo antivegf na fabricação de um medicamento para tratar câncer de mama localmente recidivado ou metastático em um sujeito e anticorpo anti-vegf para uso em um método de tratamento de câncer de mama localmente recidivado ou metastático em um sujeito"
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
BRPI0717845A2 (pt) Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
BRPI0511396A (pt) derivados de retinal e métodos para uso no tratamento de enfermidades visuais
CL2007001665A1 (es) Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria.
EA201100335A8 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
BRPI0518228A (pt) inibidores de cinesina mitótica e métodos de uso destes
UA85574C2 (uk) Ендопаразитоцидний засіб для місцевого застосування
MY158428A (en) Topical composition for the treatment of actinic keratosis
WO2007143211A3 (en) Methods for identifying agents and their use for the prevention of restenosis
NZ703411A (en) Use of markers in the diagnosis and treatment of prostate cancer
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
CY1108540T1 (el) Ταυτοποιηση θεραπευτικων ενωσεων
DOP2009000208A (es) Métodos de tratamiento del cáncer mediante administración de combinaciones de il-18 humana

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]